Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

arch agreements

--500,000100,000Total revenues

156,352208,6521,480,362892,644Operating expenses:Research and development

6,940,5647,573,25132,797,67234,416,983Marketing

1,995,716194,8335,051,0061,049,760General and administrative

3,710,7392,074,19212,499,8778,024,138Total operating expenses

12,647,0199,842,27650,348,55543,490,881Loss from operations

(12,490,667)(9,633,624)(48,868,193)(42,598,237)Interest income and other, net

227,89955,025329,290363,998Consolidated net loss

$(12,262,768)$ (9,578,599)$(48,538,903)$(42,234,239)Net loss attributable to noncontrolling interest

316,766141,6821,199,161141,682 Net loss attributable to Optimer Pharmaceuticals, Inc. common stockholders

$(11,946,002)$ (9,436,917)$(47,339,742)$(42,092,557)Basic and diluted net loss per share attributable to common stockholders

$
(0.31)$
(0.28)$
(1.25)$
(1.30)Shares used to compute basic and diluted net  loss per share attributable to common stockholders

39,140,21433,117,09537,830,45232,468,702Optimer Pharmaceuticals, Inc.Consolidated Balance SheetsYear Ended December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

$  19,861,924$ 17,054,328Short-term investments

29,553,50621,131,145Prepaid expenses and other current assets

516,859416,859Total current assets

49,932,28938,602,332Property and equipment, net

697,683672,896Long-term investments

882,000882,000Other assets

508,190498,762Total assets

$  52,020,162$ 40,655,990LIABILITIES  AND STOCKHOLDERS'  EQUITYCurrent liabilities:Accounts payable

$
2,307,820$   2,625,240Accrued expenses

2,385,0465,025,669Total current liabilities

$
4,692,866$   7,650,909Deferred rent

141,138253,474Commitments and contingencies

--Stockholders’ equity

47,186,15832,751,607Total liabilities and stockholders’ e
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The global ... of products, methods, applications, end users, and geographies. ... in the microbial identification market. This favorable growth ... (per test) and the time required for microbial ... technological advancements. Furthermore, genotypic methods have high applications ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
(Date:7/29/2014)... 29, 2014  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $515.2 million, or ... as detailed in Table 4, was $1.23 for the ... positioned to serve our clients with scale, alignment and innovative ... the health outcomes of our members," stated George Paz, chairman ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
(Date:7/29/2014)... The Mesothelioma Applied Research Foundation (Meso Foundation) along ... advocacy efforts among its members for increased participation of ... the Deadliest Cancers. , As a result of ... members: , Rep. Matt Salmon (AZ-5) – June 18, 2014, ... Lofgren (CA-19) – June 19, 2014, Rep. Adam Schiff (CA-28) ...
(Date:7/29/2014)... 2014 Daily Gossip indicates that the ... other disturbing symptoms that hemorrhoids commonly causes. The new ... natural medicine expert. , The author of H ... elimination of symptoms such as itching, burning, pain and ... about the H Miracle by visiting the official website ...
(Date:7/29/2014)... chemical alteration in a single human gene linked to ... give doctors a simple blood test to reliably predict ... described online in The American Journal of Psychiatry ... the function of the brain,s response to stress hormones ... be an unremarkable reaction to the strain of everyday ...
(Date:7/29/2014)... PHILADELPHIA Use of electroacupuncture (EA) a ... is passed between pairs of acupuncture needles ... in as little as eight weeks for early ... to the use of aromatase inhibitors (AIs) to ... placebo-controlled trial examining the intervention led by researchers ...
(Date:7/29/2014)... 30, 2014)A diet rich in soy may help feminine ... online today in Menopause , the journal of ... similar to the diet of women in Asia, produces ... menopause, similar to Asian migrants to North America, leads ... diet, and switching to soy from a Western diet ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Soy may help women's hearts if they start early 2
... conjunction with its first quarter 2009 earnings release (expected to be ... CVD ) is pleased to invite you to listen ... over the Internet on Thursday, April 30, 2009 at 9:00 a.m. ... Webcast and Slide Presentation, When: April 30, ...
... (Nasdaq: CSCX ), a global leader in automated external defibrillator ... , cardiac stress test , Holter ... EMR and HIS systems, announced today that it ... 2009 after market close. The Company has scheduled a conference call with ...
... CORDOVA, Calif. , April 30 /PRNewswire-FirstCall/ ... leading supplier of innovative products that process and store adult ... the fiscal third quarter ended March 31, 2009, on Wednesday, ... , Management will host a conference call Wednesday, ...
... scientific collaboration has discovered that an electronic nose developed ... also be used to detect odour differences in normal ... study open up new possibilities for neurosurgeons in the ... of Hope Cancer Center, along with scientists from the ...
... of healthcare on-demand patient and staff education, healthcare televisions and ... North Carolina,s member-supported statewide television network, to bring UNC-KD, a ... a day, to children,s hospitals throughout North Carolina. , ... ...
... team up to ensure international students can travel safely; Tuition Fee protection ... ... 30, 2009 -- With a rise in interest from students and faculty ... Travel Insurance Services) Corp. has teamed up with Student Funding Group (StuFund) ...
Cached Medicine News:Health News:Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 2Health News:Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 3Health News:ThermoGenesis Corp. to Announce Third Quarter Fiscal 2009 Results on May 6, 2009 2Health News:NASA's electronic nose may provide neurosurgeons with a new weapon against brain cancer 2Health News:TeleHealth Services and UNC-TV Partner to Bring Kids Channel to North Carolina Children's Hospitals 2Health News:TeleHealth Services and UNC-TV Partner to Bring Kids Channel to North Carolina Children's Hospitals 3Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 3
Inquire...
... The most energy efficient refrigerator on ... even cooling throughout the unit. The contoured ... action. The steel outer walls are coated ... and the textured steel door is reversible. ...
... F340 is a basic laboratory system for ... results can be obtained when used with ... electrode. • Fast and easy one and ... for five buffers (pH 1.68, 4.00, 7.00, ...
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
Medicine Products: